期刊文献+

维生素B12和叶酸结合二甲双胍干预2型糖尿病的临床效果 被引量:8

下载PDF
导出
摘要 目的探究维生素B12和叶酸结合二甲双胍干预2型糖尿病的临床效果。方法将2016年12月至2017年6月在本院接受治疗的120例2型糖尿病患者作为观察对象,根据入院先后实施分组,每组各30例,A组:二甲双胍单药治疗;B组:二甲双胍联合甲钴胺治疗;C组:二甲双胍联合叶酸治疗;D组:二甲双胍联合甲钴胺、叶酸治疗,对四组患者治疗前后同型半胱氨酸水平(Hcy)、叶酸水平、维生素B12水平以及并发症发生情况进行综合评价。结果D组患者治疗后的hcy水平、叶酸水平以及维生素B12水平变化不明显,A组治疗后Hcy呈增高趋势、维生素B12水平下降,与其他三组比较差异存在统计学意义(P〈0.05);且D组治疗后仅有2例患者出现并发症,占67%,显著低于A组的26.7%,其并发症率与B组、C组比较差异无统计学意义(P〈0.05)。结论维生素B12和叶酸结合二甲双胍治疗2型糖尿痛,能够维持患者Hcy、叶酸以及维生素B12水平稳定,降低血糖指标,并发症少,值得推广应用。 Objective To explore the clinical effect of vitamin BI2 and folic acid combined with metformin in type 2 diabetes mellitus. Methods In December 2016 to June 2017 in our hospital for treatment of 120 cases of patients with type 2 diabetes were selected as the research objects, according to hospital had implemented group, 30 cases in each group, group A: mefformin monotherapy. Group B: mefformin combined with a cobalt amine treatment. Group C: metformin combined with folic acid. Group D: metformin in combination with a cobalt amine, folic acid treatment, before and after treatment in patients with four groups of homocysteine levels (Hcy) , folic acid and vitamin Bl2 levels and complications occurred in comprehensive evaluation. Results D group of patients after treatment of hcy levels, folic acid and vitamin B12 levels haven't changed much, hcy showed A trend of increased after treatment group A, and vitamin B12 levels drop, the differences were statistically significant compared with the other three groups ( P〈0.05 ) . In addition, only 2 patients had complications after group D treatment, accounted for 6.7%, significantly lower than 26.7% in group A, and the complication rate was not statistically significant ( P〈0.05 ) compared with group B and group C. Conclusion Vitamin B12 and folic acid combined with metformin in the treatment of type 2 diabetes, can keep patients Hcy, folic acid and vitamin B12 levels stable, reduce blood sugar, fewer complications, worthy of popularization and application.
作者 陈书程
出处 《浙江临床医学》 2018年第8期1391-1393,共3页 Zhejiang Clinical Medical Journal
基金 浙江省绍兴市柯桥区医疗卫生自筹经费科技计划项目(2016kz009)
关键词 维生素B12 叶酸 二甲双胍 2型糖尿病 血糖指标 HCY 并发症 Vitamin B12 Folic acid Mefformin Type 2 diabetes Glycemic index Hcy Complications
  • 相关文献

二级参考文献34

  • 1陈黔妹,沈扬,樊东升.颈动脉粥样硬化与进展性卒中的相关因素研究[J].中国康复理论与实践,2004,10(12):731-732. 被引量:48
  • 2脑血管疾病分类(1995)(中、英文)[J].中华神经科杂志,1996,29(6):376-378. 被引量:430
  • 3Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DPP IV)in NASH patients, Ann Hepatol, 2007, 6(4): 242-250.
  • 4Iwasaki T, Yoneda M, Inamori M, et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepato- gastroenterology, 2011, 58(112): 2013-2015.
  • 5Itou M, Kawaguchi T, Taniguchi E, et al. Dipeptidyl peptidase IV inhibitor improves insulin resistance and steatosis in a refractory nonalcoholic fatty liver disease patient: a case report. Gastroenterology, 2012, 6(2): 538-544.
  • 6Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 2007, 30(5): 1212-1218.
  • 7Zhao G, Taunk PC, Magnin DR, et al. Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors . Bioorg Med Chem Lett, 2005, 15(18): 3992-3995.
  • 8Boulton DW, Goyal A, Li L, et al. The effects of age and gender on the single-dose, pharmacokinetics and safety of saxagliptin in healthy subjects . Diabetes, 2008, 57 Suppl. 1: A164.
  • 9陆敏,姜建东,袁存国,王军,赵艳霞.缺血性脑卒中复发患者血浆同型半胱氨酸水平变化的临床意义[J].卒中与神经疾病,2008,15(4):213-216. 被引量:21
  • 10张伟丽,祝立新,孙凯,张春玲,惠汝太,汪道文,廖玉华,万鲁虹.高同型半胱氨酸水平与脑卒中患者心脑血管事件再发风险的关系[J].临床内科杂志,2009,26(10):666-668. 被引量:43

共引文献28

同被引文献59

引证文献8

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部